Evommune, Inc. (EVMN) stock
EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$7.02−0.08 (-1.13%)
Close on Nov 17, 2026Market cap $254.77MP/E –Yield –
Earnings
Evommune's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 4, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
–
– on a year earlier
EPS, Q3 FY2026
-$0.85
-$8.07 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Evommune's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 4, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 12, 2026after the close | – | – | -$0.85 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026after the close | – | – | -$0.89 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026after the close | – | – | -$0.64 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 5, 2026after the close | $0 | – | -$1.43 | Release |
| Q3 FY2025ended Sep 30, 2025 | Dec 11, 2025after the close | $10.00M | – | -$8.07 | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Evommune has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Evommune puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Evommune filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Update
- Update
- Update
- Update
- Update
- Update
- Results
- Update
- Update
- Results
- Results
See a number that looks wrong?